4//SEC Filing
Hashad Mohamed Wa'el Ahmed 4
Accession 0000950170-24-080540
CIK 0001541157other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:30 PM ET
Size
21.5 KB
Accession
0000950170-24-080540
Insider Transaction Report
Form 4
Hashad Mohamed Wa'el Ahmed
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-06-28+5,000,000→ 5,000,000 totalExercise: $0.00Exp: 2034-06-28→ Ordinary Shares, par value $0.0001 per share (5,000,000 underlying)
Footnotes (3)
- [F1]The stock options have an exercise price of $0.001395 per ordinary share, par value $0.0001 per share ("Ordinary Share").
- [F2]Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer.
- [F3]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
Documents
Issuer
Akari Therapeutics Plc
CIK 0001541157
Entity typeother
Related Parties
1- filerCIK 0001966752
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:30 PM ET
- Size
- 21.5 KB